Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to determine whether febuxostat and benzbromarone could protect renal function in chinese, and which one could be better.
Chronic kidney disease patients with hyperuricemia and glomerular filtration rate (GFR) 20-60 ml/min were treated by febuxostat or benzbromarone. Follow up the changes of serum uric acid, serum creatinine and GFR levels. Compare the effects on renal function of these two drugs.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Febuxostat | Experimental | take orally,10-80mg per day, for 1 year,start with a low dose, and adjust the dose according to the level of uric acid |
|
| Benzbromarone | Experimental | take orally,12.5-100mg per day, for 1 year,start with a low dose, and adjust the dose according to the level of uric acid |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Febuxostat | Drug | It acts as an inhibitor of xanthine oxidase, thus lowering urate concentrations in the body |
|
| Measure | Description | Time Frame |
|---|---|---|
| serum creatinine, estimated glomerular filtration rate (eGFR) | eGFR will be estimated by CKD-EPI equation, which is most widely used recently in the world. eGFR will be calculated according to serum creatinine, age, gender and race. | up to 12th months |
| Measure | Description | Time Frame |
|---|---|---|
| urine protein | 6th months, 12th months | |
| adverse drug reaction | 1st month, 2nd months, 3rd months, 6th months, 9th months, 12th months |
Not provided
Inclusion Criteria:
Chronic kidney disease patients with glomerular filtration rate (GFR,20-60ml/min) who match one of the following criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Ai Peng, MD,PhD | Contact | pengai@hotmail.com |
| Name | Affiliation | Role |
|---|---|---|
| Ai Peng, MD, PhD | Department of Nephrology & Rheumatology, Shanghai Tenth People's Hospital | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Department of Nephrology & Rheumatology, Shanghai Tenth People's Hospital | Shanghai | Shanghai Municipality | 200072 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D051436 | Renal Insufficiency, Chronic |
| D033461 | Hyperuricemia |
| ID | Term |
|---|---|
| D051437 | Renal Insufficiency |
| D007674 | Kidney Diseases |
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000069465 | Febuxostat |
| D001553 | Benzbromarone |
| ID | Term |
|---|---|
| D013844 | Thiazoles |
| D013457 | Sulfur Compounds |
| D009930 | Organic Chemicals |
| D001393 | Azoles |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Benzbromarone | Drug | It is structurally related to the antiarrhythmic amiodarone, and it is a uricosuric agent and non-competitive inhibitor of xanthine oxidase |
|
|
| D005261 |
| Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D006573 |
| Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D001572 | Benzofurans |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |